The device, which allows coronary valve replacement without open-heart surgery, can now be purchased directly from the company. Sales between $20 million and $25 million are expected in the first three months, and sales between $150 million to $250 million are expected in the first year.
Related Articles on Medical Devices:
Medical Device Recalls Continue to Increase in Third Quarter
FDA Opens Comment Period for Medical Device Labeling
Report: Growth in Medical Device Adverse Events Outpaces Industry Growth
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
